Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 1

3(33.3%)

9Total

Phase 2(6)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01373229Phase 1Completed

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Role: lead

NCT00586690Phase 1Completed

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

Role: lead

NCT02115126Phase 2Withdrawn

Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

Role: lead

NCT00578942Phase 2Completed

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

Role: lead

NCT00511043Phase 2Terminated

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Role: lead

NCT00004143Phase 2Completed

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Role: lead

NCT00586703Phase 1Completed

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

Role: lead

NCT00580034Phase 2Completed

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Role: lead

NCT00597714Phase 2Completed

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Role: lead

All 9 trials loaded